<DOC>
	<DOCNO>NCT02122562</DOCNO>
	<brief_summary>Objective : Glutamate-based medication include N-methyl-D-aspartate ( NMDA ) receptor antagonist ketamine result rapid , robust sustain ( one week ) antidepressant effect randomize controlled trial treatment-refractory unipolar bipolar depression . Previous work group demonstrate family history alcohol dependence predict robust antidepressant response ketamine treatment-resistant unipolar bipolar depression . Recently-detoxified alcoholic affect first-degree relative display blunt psychotomimetic , cognitive neuropsychiatric effect subanesthetic dose ketamine . Also , family history alcoholism alone predict differential response intravenous alcohol . Based prior post hoc result , seek prospectively demonstrate family history alcohol dependence predict robust antidepressant response ketamine . We also explore potential biomarkers ketamine antidepressant effect treatment-refractory depressed patient risk alcohol dependence ( use physiological neurochemical response alcohol ) . Study Population : 21-65 year old treatment-resistant major depressive disorder without psychotic feature patient current major depressive episode least moderate severity recruit enrolled protocol . All subject must also free lifetime substance use disorder diagnosis exception nicotine caffeine use disorder ) psychotropic medication-free least two week prior first alcohol infusion . Our targeted number completers 50 depressed subject ( 60 sign consent account attrition ) : 25 FHP subject [ define either one first degree relative two second-degree relative alcohol dependence Family Interview Genetics Studies ( FIGS ) Family Tree Questionnaire ( FTQ ) ] 25 FHN negative subject . Design : This study single-site , open-label protocol psychotropic medication-free depressed subject admit Clinical Research Center Mood Anxiety Disorder Inpatient Research Unit ( 7-SE ) . This protocol consist two phase ( Phase I Phase II ) . The first phase consist medication taper drug-free period . The second phase three subphases : Subphase IIA ( alcohol clamp infusion # 1 neurophysiological assessment ) , IIB ( alcohol clamp infusion # 2 7 Tesla-Magnetic Resonance Spectroscopy/Imaging ( 7T-MRS/I ) ) IIC ( subanesthetic/antidepressant dose ketamine infusion 7T-MRS/I ) . Outcome Measures : The primary hypothesis/outcome measure change mean Montgomery-Asberg Depression Rating Scale ( MADRS ) total score pre-ketamine infusion baseline-to-7 day post-infusion FHP FHN group . Other exploratory measure include neurophysiological response intravenous alcohol infusion , brain neurochemical alteration intravenous alcohol infusion , brain neurochemical alteration intravenous ketamine infusion rest state ( task-free ) functional magnetic resonance image function family history alcohol use disorder .</brief_summary>
	<brief_title>The Neurophysiological Effects Intravenous Alcohol Potential Biomarkers Ketamine 's Rapid Antidepressant Effects Major Depressive Disorder</brief_title>
	<detailed_description>Objective : Glutamate-based medication include N-methyl-D-aspartate ( NMDA ) receptor antagonist ketamine result rapid , robust sustain ( one week ) antidepressant effect randomize controlled trial treatment-refractory unipolar bipolar depression . Previous work group demonstrate family history alcohol dependence predict robust antidepressant response ketamine treatment-resistant unipolar bipolar depression . Recently-detoxified alcoholic affect first-degree relative display blunt psychotomimetic , cognitive neuropsychiatric effect subanesthetic dose ketamine . Also , family history alcoholism alone predict differential response intravenous alcohol . Based prior post hoc result , seek prospectively demonstrate family history alcohol dependence predict robust antidepressant response ketamine . We also explore potential biomarkers ketamine antidepressant effect treatment-refractory depressed patient risk alcohol dependence ( use physiological neurochemical response alcohol ) . Study Population : 21-65 year old treatment-resistant major depressive disorder without psychotic feature patient current major depressive episode least moderate severity recruit enrolled protocol . All subject must also free lifetime substance use disorder diagnosis exception nicotine caffeine use disorder ) psychotropic medication-free least two week prior first alcohol infusion . Our targeted number completers 50 depressed subject ( 60 sign consent account attrition ) : 25 FHP subject [ define either one first degree relative two second-degree relative alcohol dependence Family Interview Genetics Studies ( FIGS ) Family Tree Questionnaire ( FTQ ) ] 25 FHN negative subject . Design : This study single-site , open-label protocol psychotropic medication-free depressed subject admit Clinical Research Center Mood Anxiety Disorder Inpatient Research Unit ( 7-SE ) . This protocol consist two phase ( Phase I Phase II ) . The first phase consist medication taper drug-free period . The second phase three subphases : Subphase IIA ( alcohol clamp infusion # 1 neurophysiological assessment ) , IIB ( alcohol clamp infusion # 2 7 Tesla-Magnetic Resonance Spectroscopy/Imaging ( 7T-MRS/I ) ) IIC ( subanesthetic/antidepressant dose ketamine infusion 7T-MRS/I ) . Outcome Measure : The primary hypothesis/outcome measure change mean Montgomery-Asberg Depression Rating Scale ( MADRS ) total score pre-ketamine infusion baseline-to-7 day post-infusion FHP FHN group . Other exploratory measure include neurophysiological response intravenous alcohol infusion , brain neurochemical alteration intravenous alcohol infusion , brain neurochemical alteration intravenous ketamine infusion rest state ( task-free ) functional magnetic resonance image function family history alcohol use disorder .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . 21 65 year age . 2 . A level understanding sufficient agree require test examination , sign inform consent document verify understand score great equal 90 % consent quiz . 3 . DSMIVTR diagnosis MDD , singleepisode ( 296.30 ) recurrent ( 296.20 ) without psychotic feature base clinical assessment confirm Structured Clinical Interview DSMIV Patient Version ( SCIDP ) . Subjects must experience current major depressive episode least 2 week duration . 4 . Past failure great equal two standard antidepressant trial base Antidepressant Treatment History Form ( ATHF ) . 5 . MADRS score great equal 20 baseline day ketamine infusion . EXCLUSION CRITERIA : 1 . Inadequate knowledge family mental substance use history , e.g . adoption . 2 . Current psychotic feature prior diagnosis DSMIVTR psychotic spectrum disorder , e.g . schizophrenia , schizoaffective disorder , bipolar I disorder psychotic feature , MDD psychotic feature , bipolar disorder , e.g . bipolar I disorder without psychotic feature , bipolar II disorder bipolar disorder otherwise specify ( NOS ) . 3 . Current/active DSMIVTR drug alcohol use disorder ( except caffeine nicotine dependence ) , currently seek help alcohol problem , abstinent history alcohol use disorder , nondrinker ( alcohol past year ) , history alcoholinduced flushing reaction . 4 . Pregnant nursing woman woman child bear potential use least one medically accept mean contraception ( include oral , injectable , implant birth control , condom diaphragm spermicide , intrauterine device ( IUD ) , tubal ligation , abstinence partner vasectomy ) . 5 . Serious , unstable medical conditions/problems include hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , neurologic , immunologic , hematologic disease , e.g . uncontrolled asthma , uncontrolled hyper/hypothyroidism active cancer . 6 . Presence medical illness likely alter brain morphology and/or physiology ( e.g. , hypertension , diabetes ) even control medication . 7 . Clinically significant abnormal laboratory test . 8 . Subjects one seizures without clear resolve etiology head injury loss consciousness &gt; 5 minute require hospitalization . 9 . Treatment psychiatric medication , e.g . selective serotonin reuptake inhibitor , serotonin norepinephrine reuptake inhibitor , benzodiazepine antipsychotic , least two week study phase II . 10 . Treatment fluoxetine within 5 week study phase II . 11 . Treatment devicebased treatment depression , e.g . electroconvulsive therapy ( ECT ) , transcranial magnetic stimulation ( TMS ) vagal nerve stimulation ( VNS ) , within 4 week study phase II . 12 . Lifetime history deep brain stimulation . 13 . Treatment disallow concomitant medication . 14 . Positive HIV test 15 . Presence ferromagnetic implant , e.g , heart pacemaker aneurysm clip , contraindication magnetic resonance imaging ( MRI ) , e.g . claustrophobia hearing loss . 16 . Clinicallysignificant anatomical brain abnormality detect routine brain MRI . 17 . Subjects , investigator judgment , pose current serious suicidal homicidal risk , MADRS item 10 score &gt; 4 . 18 . A current NIMH employee/staff immediate family member . 19 . Currently engage evidencebased structured psychotherapy mood and/or anxiety disorder , e.g . cognitivebehavioral therapy ( CBT ) interpersonal psychotherapy ( IPT ) . Additionally , Investigators may exclude terminate patient clinical reason .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 22, 2016</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>Major Depression</keyword>
	<keyword>Alcohol</keyword>
	<keyword>Alcohol Clamp</keyword>
	<keyword>NMDA Antagonist</keyword>
</DOC>